This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:diseases:ibs [02.10.2019] – [Higher temporal instability] sallieq | home:diseases:ibs [03.13.2019] – [Headline] sallieq | ||
---|---|---|---|
Line 2: | Line 2: | ||
====== Irritable bowel syndrome (IBS) ====== | ====== Irritable bowel syndrome (IBS) ====== | ||
+ | |||
+ | < | ||
Line 45: | Line 47: | ||
Free versus total serum 25-hydroxyvitamin D in a murine model of colitis. | Free versus total serum 25-hydroxyvitamin D in a murine model of colitis. | ||
+ | |||
+ | ==== Further researxh ==== | ||
+ | |||
+ | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | ||
+ | |||
+ | In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. | ||
+ | |||